Literature DB >> 3126499

Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli.

H Lorberboum-Galski1, D FitzGerald, V Chaudhary, S Adhya, I Pastan.   

Abstract

A cDNA clone for human interleukin 2 (IL-2) has been fused to the 5' end of a modified Pseudomonas exotoxin (PE) gene that lacks the sequences encoding the cell recognition domain. The chimeric protein IL-2-PE40 was produced in Escherichia coli. It was extremely toxic to IL-2 receptor-positive cells but had no measurable effect on cells lacking the IL-2 receptor. IL-2-PE40 might be a useful cytotoxic agent in the treatment of diseases involving IL-2 receptor-positive cells and in the treatment of allograft rejection.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3126499      PMCID： PMC279893          DOI： 10.1073/pnas.85.6.1922

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  32 in total

1.  Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions.

Authors:  M Sharon; R D Klausner; B R Cullen; R Chizzonite; W J Leonard
Journal:  Science       Date:  1986-11-14       Impact factor: 47.728

2.  Evidence for enhanced interleukin 2 (IL-2) secretion and IL-2 receptor presentation by synovial fluid lymphocytes in rheumatoid arthritis.

Authors:  G Lemm; H Warnatz
Journal:  Clin Exp Immunol       Date:  1986-04       Impact factor: 4.330

3.  Intestinal lymphocyte subpopulations in inflammatory bowel disease: an analysis by immunohistological and cell isolation techniques.

Authors:  W S Selby; G Janossy; M Bofill; D P Jewell
Journal:  Gut       Date:  1984-01       Impact factor: 23.059

4.  A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor.

Authors:  W J Leonard; J M Depper; T Uchiyama; K A Smith; T A Waldmann; W C Greene
Journal:  Nature       Date:  1982-11-18       Impact factor: 49.962

5.  The interleukin-2 T-cell system: a new cell growth model.

Authors:  D A Cantrell; K A Smith
Journal:  Science       Date:  1984-06-22       Impact factor: 47.728

6.  Thyrotropin-releasing hormone-diphtheria toxin-related polypeptide conjugates. Potential role of the hydrophobic domain in toxin entry.

Authors:  P Bacha; J R Murphy; S Reichlin
Journal:  J Biol Chem       Date:  1983-02-10       Impact factor: 5.157

7.  Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats.

Authors:  J W Kupiec-Weglinski; T Diamantstein; N L Tilney; T B Strom
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

8.  In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis.

Authors:  G F Bottazzo; B M Dean; J M McNally; E H MacKay; P G Swift; D R Gamble
Journal:  N Engl J Med       Date:  1985-08-08       Impact factor: 91.245

9.  Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution.

Authors:  V S Allured; R J Collier; S F Carroll; D B McKay
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 12.779

10.  Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice.

Authors:  R L Kirkman; L V Barrett; G N Gaulton; V E Kelley; A Ythier; T B Strom
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307
View more
  24 in total

Review 1.  Immunotherapy through the IL-2 receptor.

Authors:  H A Verheul; M Verveld; E S Bos
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

2.  Mechanism of action of interleukin-2 (IL-2)-Bax, an apoptosis-inducing chimaeric protein targeted against cells expressing the IL-2 receptor.

Authors:  Rami Aqeilan; Rotem Kedar; Ahmi Ben-Yehudah; Haya Lorberboum-Galski
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

3.  Pharmacokinetics of the recombinant fusion protein DAB486IL-2 in animal models.

Authors:  P Bacha; S Forte; N Kassam; J Thomas; D Akiyoshi; C Waters; J Nichols; M Rosenblum
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Effect of IL-2-Bax, a novel interleukin-2-receptor-targeted chimeric protein, on bleomycin lung injury.

Authors:  Michael J Segel; Rami Aqeilan; Keren Zilka; Haya Lorberboum-Galski; Shulamit B Wallach-Dayan; Michael W Conner; Thomas G Christensen; Raphael Breuer
Journal:  Int J Exp Pathol       Date:  2005-10       Impact factor: 1.925

5.  Expression of diphtheria toxin fragment A and hormone-toxin fusion proteins in toxin-resistant yeast mutants.

Authors:  J P Perentesis; F S Genbauffe; S A Veldman; C L Galeotti; D M Livingston; J W Bodley; J R Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

Review 6.  The treatment of lupus nephritis.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

Review 7.  Immunoconjugates in the management of hairy cell leukemia.

Authors:  Robert J Kreitman; Ira Pastan
Journal:  Best Pract Res Clin Haematol       Date:  2015-10-09       Impact factor: 3.020

8.  Enhancement of cell type specificity by quantitative modulation of a chimeric ligand.

Authors:  Pablo Cironi; Ian A Swinburne; Pamela A Silver
Journal:  J Biol Chem       Date:  2008-01-29       Impact factor: 5.157

9.  Human fusion proteins between interleukin 2 and IgM heavy chain are cytotoxic for cells expressing the interleukin 2 receptor.

Authors:  H Vié; T Gauthier; R Breathnach; M Bonneville; A Godard; J Dietrich; G Karam; M C Gesnel; M A Peyrat; Y Jacques; J P Soulillou
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

Review 10.  Lupus nephritis in childhood and adolescence.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.